微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 17.85% | -19.7% | -8.16% | 137/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 19.43% | -19.98% | -9.36% | 139/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 21.44% | -11.83% | -0.25% | 137/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 21.49% | -8.78% | -3.29% | 139/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 22.23% | 8.33% | -8.48% | 134/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 24.29% | 1.01% | -0.12% | 133/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 24.32% | -6.15% | 3.2% | 133/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 23.56% | -19.5% | 14.84% | 133/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 20.52% | -34.43% | -14.67% | 132/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 24.04% | -35.71% | -7.2% | 134/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 25.91% | -35.46% | -11.48% | 125/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 29.27% | -31.53% | -6.44% | 120/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 31.29% | -29.3% | -16.34% | 108/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 37.4% | -14.98% | -6.84% | 113/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 40.15% | -13.64% | -6.1% | 93/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 42.75% | -9.82% | -3.38% | 91/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 44.25% | -2.24% | 0.6% | 78/158 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 43.99% | 2.96% | -5.38% | 96/158 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 46.49% | 10.67% | -1.94% | 77/158 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 47.41% | 13.93% | 4.74% | 81/158 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 45.27% | 15.3% | 5.95% | 73/158 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 42.72% | 5.56% | 1.7% | 92/158 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 42.01% | 1.37% | 0.95% | 73/158 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 41.62% | 3.64% | 6% | 78/158 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 39.26% | 1.69% | -3% | 76/158 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 40.47% | 7.91% | -2.34% | 94/158 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 41.44% | 5.5% | 3.21% | 69/158 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 40.15% | 5.9% | 4% | 71/158 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 38.61% | 0.75% | 2.94% | 75/158 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 37.51% | -1.68% | -4.52% | 83/158 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 39.28% | 3.66% | 3.61% | 61/158 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 37.92% | 0.49% | -1.05% | 70/158 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 38.32% | -1.71% | 0.46% | 53/158 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 38.15% | 2.66% | 0.66% | 72/158 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 37.9% | 3.34% | 0.44% | 49/158 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 37.73% | 2% | -3.22% | 56/158 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 38.99% | 2% | 4.93% | 43/158 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 37.16% | 17.93% | 1.32% | 62/158 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 36.67% | 2% | 16.4% | 47/158 | 44.69% | 舒泰神 | 94.38% | 行业排名> |